Intralesional epidermal growth factor for diabetic foot wounds: the first cases in Turkey

Intralesional recombinant epidermal growth factor (EGF) was produced in the Centre for Genetic Engineering and Biotechnology (CIGB), Cuba, in 1988 and licensed in 2006. Because it may accelerate wound healing, it is a potential new treatment option in patients with a diabetic foot wound (whether inf...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetic foot & ankle 2015-01, Vol.6 (1), p.28419-28419
Hauptverfasser:	Ertugrul, Bulent M., Buke, Cagri, Ersoy, Ozlem Saylak, Ay, Bengisu, Demirez, Dilek Senen, Savk, Oner
Format:	Artikel
Sprache:	eng
Schlagworte:	Amputation Clinical College professors Colleges & universities Diabetes diabetic foot Epidermal growth factor Foot diseases Funding Hospitalization Hospitals Infections Infectious diseases intralesional epidermal growth factor Medicine Microbiology Mortality Plastic surgery Skin & tissue grafts treatment Ulcers Wound healing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!